TriSalus Life Sciences Inc TLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
-
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
-
TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky
-
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
-
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
-
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
Trading Information
- Previous Close Price
- $3.30
- Day Range
- $3.16–3.33
- 52-Week Range
- $2.20–7.95
- Bid/Ask
- $3.16 / $3.50
- Shares Outstanding
- 61.42M
- Market Cap
- $194.69M
- Volume/Avg
- 304,392 / 355,964
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 102
- Website
- https://www.trisaluslifesci.com
Valuation
|
Metric
|
TLSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 15.20 |
Price/Sales | 3.10 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLSI
|
|---|---|
Quick Ratio | 5.24 |
Current Ratio | 5.78 |
Interest Coverage | −3.84 |
Quick Ratio
TLSI
Profitability
|
Metric
|
TLSI
|
|---|---|
Return on Assets (Normalized) | −57.04% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −148.08% |
Return on Assets
TLSI
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Gpxxtfb | Dlpmjyx | $159B | |||
| Stryker Corp
SYK
| Gtwcyqypd | Qyzrg | $117B | |||
| Medtronic PLC
MDT
| Jhkkdfrww | Wqfdwd | $105B | |||
| Boston Scientific Corp
BSX
| Cnswbdj | Dgwlbyw | $72B | |||
| Edwards Lifesciences Corp
EW
| Pfclrqtjl | Pvmwbd | $49B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| Kpbrsyf | Ywgj | $29B | |||
| DexCom Inc
DXCM
| Fyxcshlpp | Djfsfv | $28B | |||
| Koninklijke Philips NV ADR
PHG
| Gll | Myxpv | $25B | |||
| Steris PLC
STE
| Hsnpsndyq | Mmkpmt | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| Nnqvzqbzz | Xlp | $17B |
United States